718 / 1835
Does
90
Y Ibritumomab Consolidation after first line R-Chemo
Induction in Follicular Lymphoma improve outcome?
FIT study (R-chemo subgroup; n=59)
CR rate after Zevalin : 93% (controls: 71%)
PFS at 84 months: 64% Zevalin vs 23% controls (median
follow-up: 71.6 months)
• ECOG 1496
6-8 x chemo
- CR/PR/SD
randomised 16 cycles of Rituximab – similar results for PFS
Randomised (
90
Y Ibritumomab) vs in Rituximab maintenance
(ROZETTA study) no significant difference in PFS